Kang Wei, managing director for the R&D-based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment, shares her priorities for RDPAC in the next few years, her members’ contribution to the Chinese healthcare environment and the national Healthy China 2030 strategy, as well as the importance of correctly valuing innovation.
The global R&D and innovation system often involves close collaboration between big multinationals, capital and local start-ups – and this sort of environment is developing in China as well
